The advantage of proton therapy is reduction of treatment volumes relative to those feasible with conventinal photon therapy. The consequence is that the radiation dose to the target can be raised, with a resultant increse in tumor control probability. Proton beams, however, yield no biological gains because their biological properties are similar to conventional low LET radiations. As more sophisticated technologies are needed, there have been many advances which are applicable to photon therapy; 3-D treatment planning, DVH analysis, and systems for positioning, etc.
As of January 1994, a total of about 13, 000 cases were reported as having had treatmemts with proton beams in 16 centers world wide. The. tumor sites for those include uveal melanoma (30-40%), intra-cranial small targets (40%), and others. Uveal melanomas had been most extensively treated with 70Gy/5fx or 60Gy/4fx which resulted in local control and survival rates of>96%and 80%, respectively. For chordoma and chondrosarcoma of the skull base and cervical spine, the 5 year local control rates were 65% and 91%, respectively. Promising results are also being obtained for headand neck and pelvic tumors. Deeper-seated tumors have been treated only at Tsukuba University with successful results in some anatomic sites. Among these, inoperable primary hepatocellular carcinomas were effectively treated with a total dose of 75-85Gy (3.0-4.5Gy/fx). The 3 year survival rates for all patients, Child A+B patients, and Child A patients were 38%, 47%, and 60%, respectively, which compare favorably to other modalities.
These successful results of world wide proton therapy have led us to the conclusion that a hospital-based proton facility will provide opportunities for additional patients to be treated with protons. Thus, new plans are proposed from more than 10 institutions to build a new treatment center or upgrade the energy of currently available proton beams.
View full abstract